Menu

Cell Signaling and Metabolism: Bridging a Gap in Cancer Therapies

The Scientist is bringing together a panel of experts to discuss their research into an exciting and recently acknowledged hallmark of cancer.

Jun 29, 2018
The Scientist Creative Services Team

 

FREE Webinar

Wednesday, October 24, 2018
2:30-4:00 PM Eastern Time
Register Now

That cancer cells display an altered metabolism has been known for almost a century, but the cell-signaling mechanisms responsible for this phenomenon are just beginning to be understood, with some drugs targeting key regulators of both cell metabolism and tumor progression. The repurposing of old drugs for the activation and/or inhibition of proteins at the center of the cell-signaling and metabolism web has been a popular strategy for addressing these challenges. Drugs like metformin, chloroquine, and various statins are just a few examples of those in clinical trials. They offer a cost-effective advantage in addition to an already-established pharmacokinetic and pharmacodynamic profile. To further explore cell metabolism as a novel avenue of drug discovery based on already-established cell signaling mechanisms essential for tumor progression, The Scientist is bringing together a panel of experts to discuss their research into this exciting and recently acknowledged hallmark of cancer. 

Topics to be covered:

  • Metabolic symbioses in tumor microenvironments
  • Uncovering metabolic bottlenecks in genetic subtypes of lung cancer

Register Now

Meet the Speakers:

M. Celeste Simon, PhD
Scientific Director and Investigator, Abramson Family Cancer Research Institute
Associate Director-Shared Resources, Abramson Cancer Center
Rubenstein Professor, Department of Cell and Developmental Biology
University of Pennsylvania Perelman School of Medicine

 

Thales Papagiannakopoulos, PhD
Assistant Professor
Department of Pathology
NYU School of Medicine

 

July 2018

Climate Change

Which species are most vulnerable?

Marketplace

Sponsored Product Updates

New England Biolabs® Launches NEBNext Direct® Custom Ready Panels for Efficient Targeted Re-sequencing

New England Biolabs® Launches NEBNext Direct® Custom Ready Panels for Efficient Targeted Re-sequencing

New England Biolabs (NEB®) today announced the launch of the NEBNext Direct Custom Ready Panels. The new panels — coupled with the proprietary NEBNext Direct target enrichment technology — enable the rapid development and deployment of a customized target enrichment panel by allowing users to select from an extensive library of genes to produce sequencing data with high specificity and coverage uniformity.

The Journey From Features To Compound Identification In Metabolomics: When Will We Get There?

The Journey From Features To Compound Identification In Metabolomics: When Will We Get There?

In this eBook, learn about advancements in untargeted metabolomic workflow, including improved standards, guidelines, databases, and more!

Mass Spectrometry For Advanced Proteomics: A Revolution In Biological Research

Mass Spectrometry For Advanced Proteomics: A Revolution In Biological Research

In this eBook, learn more about proteins through advanced proteomics, via crosslinking, glycomics, ultra high-res spectrometry, and more!